A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

NCT07227168 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma HNSCC
Non-Small Cell Lung Cancer NSCLC
Esophageal Cancer
Gastric Cancer
Colorectal Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
Cervical Cancer
Endometrial Cancer
Urothelial Cancer

Interventions

DRUG: STRO-004
DRUG: Pembrolizumab

Sponsor

Sutro Biopharma, Inc.